Competitor Analysis: Influenza Vaccines

Publisher: La Merie Publishing
Pages: 123
Format: PDF
Product Line:
Competitor Analysis
Product Code: LMCA0116
Release Date: May of 2011

500.00 €
Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no),
Delivery costs do not apply or are included.
License:
You can also order this product via email or fax , please download the Order Form
Need more information?
Ask a question about this product

Influenza Vaccines

Product description

The present Competitive Intelligence Report about Influenza Vaccines provides a competitor evaluation in the field of marketed and novel prophylactic vaccines against seasonal and pandemic influenza viruses. Presentation of the vaccines is structured according to the manufacturing process: propagated in hens’ eggs or in cell culture, recombinant protein based vaccines and DNA based vaccines. Product description considers use of adjuvants and preservatives. Vaccines with nasal delivery are highlighted. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently marketed vaccines and active projects in research and development for prophylaxis of seasonal and pandemic influenza disease. In addition, the report lists company-specific product portfolios and R&D pipelines of influenza vaccines on the market and in R&D. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

Index

1. Seasonal influenza vaccines
1a) Cell-culture produced seasonal influenza vaccines
1b) Egg-produced seasonal influenza vaccines
1c) Recombinant Seasonal influenza vaccines
1d) DNA-based seasonal influenza vaccines
1e) Nasal delivery of seasonal influenza vaccines
1f) Other seasonal influenza vaccines

2) Pandemic (swine) A(H1N1) influenza vaccines
2a) Cell-culture produced pandemic (swine) A(H1N1) influenza vaccines

2b) Egg-produced pandemic (swine) A(H1N1) influenza vaccines

2c) Recombinant pandemic (swine) A(H1N1) influenza vaccines
2d) DNA-based pandemic (swine) A(H1N1) influenza vaccines
2e) Nasal delivery of pandemic (swine) A(H1N1) influenza vaccines
2f) Other pandemic (swine) A(H1N1) influenza vaccines

3) Pandemic (avian) H5N1 influenza vaccines
3a) Cell culture-produced pandemic (avian) H5N1 influenza vaccines
3b) Egg-produced pandemic (avian) H5N1 influenza vaccines
3c) Recombinant pandemic (avian) H5N1 influenza vaccines
3d) DNA-based pandemic (avian) H5N1 influenza vaccines
3e) Nasal delivery of pandemic (avian) H5N1 influenza vaccines
3f) Other pandemic (avian) H5N1 influenza vaccines

4) Other & unspecified pandemic influenza vaccines

5) Universal influenza vaccines

Corporate Influenza Vaccine Product Portfolios and R&D Pipelines

A*STAR
Abbott
AlphaVax
Ajanta Pharma
Antigen Express
Astellas Pharma
AstraZeneca
Avimex Laboratories
Avir Green Hills Biotechnology
Baxter
Beijing Tiantan Biological Products
Bharat Biotech
Biological E
BiondVax Pharmaceuticals
Bionor Immuno
BioSante Pharmaceuticals
Changchun Institute of Biological Products
CSL Limited
CytoGenix
Cytos Biotechnology
Dynavax Technologies
Emergent BioSolutions
FluGen
Fraunhofer
G-Con
GenPhar
GlaxoSmithKline (GSK)
GlobeImmune
Green Cross
Hualan Biological Engineering Inc
Intercell
iBio, Inc.
Immune Targeting Systems
Immuno-Vaccine Technologies
Inovio
Inviragen
Jiangsu Yanshen Biological Technology
Johnson & Johnson (J&J)
Juvaris Bio-Therapeutics
Lanzhou Institute of Biological Products (LIBP)
Liquidia Technologies
Medicago
Mellow Hope (HTDS)
Merck & Co.
Mogam Research Institute
NanoBio
Nano-therapeutics
NasVax
National Institute of Allergy and Infectious Diseases (NIAID)
Novartis
Novavax
Okairos
Panacea Biotech
Pevion Biotech
Protein Sciences
Sanofi-Aventis
Sanofi Pasteur
SEEK
Shanghai Institute of Biological Products
Shenzhen Neptunus Interlong Bio-technique Company (Interlong)
Sinovac Biotech
SK Chemicals
Solvay Biologicals
TechnoVax
Temasek
UMN Pharma
University of Wisconsin
Variation Biotechnologies
Vaxart
Vaxin
VaxInnate
Vical
Zhejiang Tianyuan Bio-Pharmaceutical Co
Zydus Cadila

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.


The above shown price refers to a Single User License. Please contact us for prices of departmental, site or global product licenses.

This Report is NOT a downloadable item but will be delivered via email within 24 h (working days only).

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top